Proteasome Inhibitors as Immunosuppressants: Biological Rationale and Clinical Experience

Seminars in Hematology

Volumn 49, Issue 3, 2012, Pages 270-276

  Moran, Eva ^a   Carbone, Federico ^a   Augusti, Valeria ^a   Patrone, Franco ^a   Ballestrero, Alberto ^a   Nencioni, Alessio ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; GAMMA INTERFERON; METHOTREXATE; PROTEASOME INHIBITOR; TACROLIMUS; TUMOR NECROSIS FACTOR ALPHA;

ACUTE GRAFT VERSUS HOST DISEASE; ALLERGIC ENCEPHALOMYELITIS; ALLOGENEIC STEM CELL TRANSPLANTATION; ANTIBODY MEDIATED GRAFT REJECTION; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIGEN PRESENTATION; ARTHRITIS; ARTICLE; AUTOIMMUNE HEMOLYTIC ANEMIA; B LYMPHOCYTE; CELL FUNCTION; CELL SURVIVAL; CELL TYPE; COLITIS; CYTOKINE RELEASE; DENDRITIC CELL; DRUG CYTOTOXICITY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INHIBITION; EVIDENCE BASED MEDICINE; GLOMERULONEPHRITIS; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HLA MATCHING; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOPATHOLOGY; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; LUNG TRANSPLANTATION; LYMPHOCYTOPENIA; MYASTHENIA GRAVIS; MYELOMA; NONHUMAN; OUTCOME ASSESSMENT; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS INHIBITION; PSORIASIS; REDUCED INTENSITY CONDITIONING; SIGNAL TRANSDUCTION; SKIN ALLERGY; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE; TISSUE INJURY;

ANIMALS; ANTIBODIES; BORONIC ACIDS; GRAFT REJECTION; GRAFT VS HOST DISEASE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEASOME INHIBITORS; PYRAZINES;

EID: 84862653224     PISSN: 00371963     EISSN: 15328686     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2012.04.004     Document Type: Article

References (67)

1. Chen D., Frezza M., Schmitt S., Kanwar J., Q P.D., et al. Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives. Curr Cancer Drug Targets 2011, 11:239-253.
2. Hideshima T., Richardson P., Chauhan D., et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 2001, 61:3071-3076.
3. Palombella V.J., Rando O.J., Goldberg A.L., Maniatis T. The ubiquitin-proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappa B. Cell 1994, 78:773-785.
4. van der Bruggen P., Van den Eynde B.J. Processing and presentation of tumor antigens and vaccination strategies. Curr Opin Immunol 2006, 18:98-104.
5. Wu J. On the role of proteasomes in cell biology and proteasome inhibition as a novel frontier in the development of immunosuppressants. Am J Transplant 2002, 2:904-912.
6. Zaiss D.M., Bekker C.P., Grone A., Lie B.A., Sijts A.J. Proteasome immunosubunits protect against the development of CD8 T cell-mediated autoimmune diseases. J Immunol 2011, 187:2302-2309.
7. Chang J.T., Ciocca M.L., Kinjyo I., et al. Asymmetric proteasome segregation as a mechanism for unequal partitioning of the transcription factor T-bet during T lymphocyte division. Immunity 2011, 34:492-504.
8. Wang X., Ottosson A., Ji C., et al. Proteasome inhibition induces apoptosis in primary human natural killer cells and suppresses NKp46-mediated cytotoxicity. Haematologica 2009, 94:470-478.
9. Sinn D.I., Lee S.T., Chu K., et al. Proteasomal inhibition in intracerebral hemorrhage: neuroprotective and anti-inflammatory effects of bortezomib. Neurosci Res 2007, 58:12-18.
10. Jagannath S., Barlogie B., Berenson J., et al. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol 2004, 127:165-172.
11. O'Connor O.A., Wright J., Moskowitz C., et al. Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol 2005, 23:676-684.
12. Chanan-Khan A., Sonneveld P., Schuster M.W., et al. Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study. J Clin Oncol 2008, 26:4784-4790.
13. + T-cell counts in patients with multiple myeloma treated with bortezomib. Clin Lymphoma Myeloma Leuk 2010, 10:134-137.
14. Nencioni A., Garuti A., Schwarzenberg K., et al. Proteasome inhibitor-induced apoptosis in human monocyte-derived dendritic cells. Eur J Immunol 2006, 36:681-689.
15. Sun K., Welniak L.A., Panoskaltsis-Mortari A., et al. Inhibition of acute graft-versus-host disease with retention of graft-versus-tumor effects by the proteasome inhibitor bortezomib. Proc Natl Acad Sci U S A 2004, 101:8120-8125.
16. Blanco B., Perez-Simon J.A., Sanchez-Abarca L.I., et al. Bortezomib induces selective depletion of alloreactive T lymphocytes and decreases the production of Th1 cytokines. Blood 2006, 107:3575-3583.
17. + T cells preserves natural regulatory T cells and allows the emergence of a distinct suppressor T-cell population. Haematologica 2009, 94:975-983.
18. Blanco B., Sanchez-Abarca L.I., Caballero-Velazquez T., Santamaria C., Inoges S., Perez-Simon J.A. Depletion of alloreactive T-cells in vitro using the proteasome inhibitor bortezomib preserves the immune response against pathogens. Leuk Res 2011, 35:1412-1415.
19. Cenci S., Mezghrani A., Cascio P., et al. Progressively impaired proteasomal capacity during terminal plasma cell differentiation. embo j 2006, 25:1104-1113.
20. Cascio P., Oliva L., Cerruti F., et al. Dampening Ab responses using proteasome inhibitors following in vivo B cell activation. Eur J Immunol 2008, 38:658-667.
21. Perry D.K., Burns J.M., Pollinger H.S., et al. Proteasome inhibition causes apoptosis of normal human plasma cells preventing alloantibody production. Am J Transplant 2009, 9:201-209.
22. Opferman J.T., Letai A., Beard C., Sorcinelli M.D., Ong C.C., Korsmeyer S.J. Development and maintenance of B and T lymphocytes requires antiapoptotic MCL-1. Nature 2003, 426:671-676.
23. Nijhawan D., Fang M., Traer E., et al. Elimination of Mcl-1 is required for the initiation of apoptosis following ultraviolet irradiation. Genes Dev 2003, 17:1475-1486.
24. Nencioni A., Hua F., Dillon C.P., et al. Evidence for a protective role of Mcl-1 in proteasome inhibitor-induced apoptosis. Blood 2005, 105:3255-3262.
25. Steinman R.M. Dendritic cells: understanding immunogenicity. Eur J Immunol 2007, 37(Suppl 1):S53-S60.
26. Nencioni A., Schwarzenberg K., Brauer K.M., et al. Proteasome inhibitor bortezomib modulates TLR4-induced dendritic cell activation. Blood 2006, 108:551-558.
27. Straube C., Wehner R., Wendisch M., et al. Bortezomib significantly impairs the immunostimulatory capacity of human myeloid blood dendritic cells. Leukemia 2007, 21:1464-1471.
28. Subklewe M., Sebelin-Wulf K., Beier C., et al. Dendritic cell maturation stage determines susceptibility to the proteasome inhibitor bortezomib. Hum Immunol 2007, 68:147-155.
29. Hirai M., Kadowaki N., Kitawaki T., et al. Bortezomib suppresses function and survival of plasmacytoid dendritic cells by targeting intracellular trafficking of Toll-like receptors and endoplasmic reticulum homeostasis. Blood 2011, 117:500-509.
30. Vanderlugt C.L., Rahbe S.M., Elliott P.J., Dal Canto M.C., Miller S.D. Treatment of established relapsing experimental autoimmune encephalomyelitis with the proteasome inhibitor PS-519. J Autoimmun 2000, 14:205-211.
31. Hosseini H., Andre P., Lefevre N., et al. Protection against experimental autoimmune encephalomyelitis by a proteasome modulator. J Neuroimmunol 2001, 118:233-244.
32. Lee S.W., Kim J.H., Park Y.B., Lee S.K. Bortezomib attenuates murine collagen-induced arthritis. Ann Rheum Dis 2009, 68:1761-1767.
33. Yannaki E., Papadopoulou A., Athanasiou E., et al. The proteasome inhibitor bortezomib drastically affects inflammation and bone disease in adjuvant-induced arthritis in rats. Arthritis Rheum 2010, 62:3277-3288.
34. Schmidt N., Gonzalez E., Visekruna A., et al. Targeting the proteasome: partial inhibition of the proteasome by bortezomib or deletion of the immunosubunit LMP7 attenuates experimental colitis. Gut 2010, 59:896-906.
35. Neubert K., Meister S., Moser K., et al. The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis. Nat Med 2008, 14:748-755.
36. Ichikawa H.T., Conley T., Muchamuel T., et al. Beneficial effect of novel proteasome inhibitors in murine lupus via dual inhibition of type I interferon and autoantibody secreting cells. Arthritis Rheum 2012, 64:493-503.
37. Gomez A.M., Vrolix K., Martinez-Martinez P., et al. Proteasome inhibition with bortezomib depletes plasma cells and autoantibodies in experimental autoimmune myasthenia gravis. J Immunol 2011, 186:2503-2513.
38. Bontscho J., Schreiber A., Manz R.A., Schneider W., Luft F.C., Kettritz R. Myeloperoxidase-specific plasma cell depletion by bortezomib protects from anti-neutrophil cytoplasmic autoantibodies-induced glomerulonephritis. J Am Soc Nephrol 2011, 22:336-348.
39. Yanaba K., Yoshizaki A., Muroi E., et al. The proteasome inhibitor bortezomib inhibits T cell-dependent inflammatory responses. J Leukoc Biol 2010, 88:117-122.
40. Luo H., Wu Y., Qi S., Wan X., Chen H., Wu J. A proteasome inhibitor effectively prevents mouse heart allograft rejection. Transplantation 2001, 72:196-202.
41. Vodanovic-Jankovic S., Hari P., Jacobs P., Komorowski R., Drobyski W.R. NF-kappaB as a target for the prevention of graft-versus-host disease: comparative efficacy of bortezomib and PS-1145. Blood 2006, 107:827-834.
42. Sun K., Wilkins D.E., Anver M.R., et al. Differential effects of proteasome inhibition by bortezomib on murine acute graft-versus-host disease (GVHD): delayed administration of bortezomib results in increased GVHD-dependent gastrointestinal toxicity. Blood 2005, 106:3293-3299.
43. Sun K., Li M., Sayers T.J., Welniak L.A., Murphy W.J. Differential effects of donor T-cell cytokines on outcome with continuous bortezomib administration after allogeneic bone marrow transplantation. Blood 2008, 112:1522-1529.
44. Polzer K., Neubert K., Meister S., et al. Proteasome inhibition aggravates tumor necrosis factor-mediated bone resorption in a mouse model of inflammatory arthritis. Arthritis Rheum 2011, 63:670-680.
45. Tung D., Cheung P.H., Kaur P., et al. Anti-inflammatory and immunomodulatory effects of bortezomib in various in vivo models. Pharmacology 2011, 88:100-113.
46. Levine M.H., Abt P.L. Treatment options and strategies for antibody mediated rejection after renal transplantation. Semin Immunol 2012, 24:136-142.
47. Shimizu A., Colvin R.B. Pathological features of antibody-mediated rejection. Curr Drug Targets Cardiovasc Haematol Disord 2005, 5:199-214.
48. Everly M.J., Everly J.J., Susskind B., et al. Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection. Transplantation 2008, 86:1754-1761.
49. Raghavan R., Jeroudi A., Achkar K., et al. Bortezomib in kidney transplant desensitization: a case report. Clin Transpl 2009, 339-342.
50. Pavlakis M. Case presentations on two patients who received bortezomib for antibody mediated rejection at BIDMC. Clin Transpl 2009, 343-345.
51. Walsh R.C., Brailey P., Girnita A., et al. Early and late acute antibody-mediated rejection differ immunologically and in response to proteasome inhibition. Transplantation 2011, 91:1218-1226.
52. Diwan T.S., Raghavaiah S., Burns J.M., Kremers W.K., Gloor J.M., Stegall M.D. The impact of proteasome inhibition on alloantibody-producing plasma cells in vivo. Transplantation 2011, 91:536-541.
53. Flechner S.M., Fatica R., Askar M., et al. The role of proteasome inhibition with bortezomib in the treatment of antibody-mediated rejection after kidney-only or kidney-combined organ transplantation. Transplantation 2010, 90:1486-1492.
54. Leyva S., Marino L.A., Alberu J., Morales-Buenrostro L.E. Bortezomib for acute humoral rejection treatment at the Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran in Mexico City: an update. Clin Transpl 2010, 369-382.
55. Hardinger K.L., Alford K., Murillo D. Bortezomib as rescue therapy for antibody mediated rejection: a single-center experience. Clin Transpl 2010, 429-436.
56. Everly M.J., Terasaki P.I., Hopfield J., Trivedi H.L., Kaneku H. Protective immunity remains intact after antibody removal by means of proteasome inhibition. Transplantation 2010, 90:1493-1498.
57. Patel J., Everly M., Chang D., Kittleson M., Reed E., Kobashigawa J. Reduction of alloantibodies via proteosome inhibition in cardiac transplantation. J Heart Lung Transplant 2011, 30:1320-1326.
58. Govil A., Walsh R.C., Tevar A., et al. Bortezomib-based treatment of antibody mediated rejection in pancreas allograft recipients. Clin Transpl 2009, 443:453.
59. Neumann J., Tarrasconi H., Bortolotto A., Machuca T., Canabarro R., Sporleder H., et al. Acute humoral rejection in a lung recipient: reversion with bortezomib. Transplantation 2010, 89:125-126.
60. Chan K.M., Lee C.S., Wu T.J., Lee C.F., Chen T.C., Lee W.C. Clinical perspective of acute humoral rejection after blood type-compatible liver transplantation. Transplantation 2011, 91:e29-e30.
61. Island E.R., Gonzalez-Pinto I.M., Tsai H.L., et al. Successful treatment with bortezomib of a refractory humoral rejection of the intestine after multivisceral transplantation. Clin Transpl 2009, 465-469.
62. Koreth J., Stevenson K.E., Kim H.T., et al. Bortezomib, tacrolimus, and methotrexate for prophylaxis of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation from HLA-mismatched unrelated donors. Blood 2009, 114:3956-3959.
63. Kuroda J., Kobayashi T., Tsutsumi Y., et al. Bortezomib for post-allogeneic hematopoietic stem transplantation relapse and GVHD in multiple myeloma: a single institute experience. Int J Hematol 2010, 92:669-672.
64. Kroger N., Zabelina T., Ayuk F., et al. Bortezomib after dose-reduced allogeneic stem cell transplantation for multiple myeloma to enhance or maintain remission status. Exp Hematol 2006, 34:770-775.
65. Carson K.R., Beckwith L.G., Mehta J. Successful treatment of IgM-mediated autoimmune hemolytic anemia with bortezomib. Blood 2010, 115:915.
66. Danchaivijitr P., Yared J., Rapoport A.P. Successful treatment of IgG and complement-mediated autoimmune hemolytic anemia with bortezomib and low-dose cyclophosphamide. Am J Hematol 2011, 86:331-332.
67. Frohlich K., Holle J.U., Aries P.M., Gross W.L., Moosig F. Successful use of bortezomib in a patient with systemic lupus erythematosus and multiple myeloma. Ann Rheum Dis 2011, 70:1344-1345.